Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

<p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5:...

Полное описание

Сохранить в:

Библиографические подробности
Главный автор:	H. Josh Jang (15206898) (author)
Другие авторы:	Galen Hostetter (15053070) (author), Alexander W. Macfarlane (15206901) (author), Zachary Madaj (15206904) (author), Eric A. Ross (15019395) (author), Toshinori Hinoue (15206907) (author), Justin R. Kulchycki (15206910) (author), Ryan S. Burgos (15206913) (author), Mahvish Tafseer (15206916) (author), R. Katherine Alpaugh (15206919) (author), Candice L. Schwebel (15206922) (author), Rutika Kokate (15206925) (author), Daniel M. Geynisman (15206928) (author), Matthew R. Zibelman (15206931) (author), Pooja Ghatalia (15206934) (author), Peter W. Nichols (15206937) (author), Woonbok Chung (15206940) (author), Jozef Madzo (14923007) (author), Noah M. Hahn (15206943) (author), David I. Quinn (15012291) (author), Jean-Pierre J. Issa (15109358) (author), Michael J. Topper (15206946) (author), Stephen B. Baylin (15045804) (author), Hui Shen (10996894) (author), Kerry S. Campbell (9724036) (author), Peter A. Jones (14941116) (author), Elizabeth R. Plimack (15044781) (author)
Опубликовано:	2025
Предметы:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade Small Molecule Agents Epigenetic-targeted agents
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
по: Roger Li (17078665)
Опубликовано: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
по: Giuseppe Basile (15051269)
Опубликовано: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
по: Niklas Klümper (15048887)
Опубликовано: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
по: Niklas Klümper (15048887)
Опубликовано: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
по: John A. Ligon (15024477)
Опубликовано: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
по: James S. Wilmott (15008931)
Опубликовано: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
по: James S. Wilmott (15008931)
Опубликовано: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
по: Ruiyun Zhang (17142498)
Опубликовано: (2025)

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
по: Yansong Lin (16374208)
Опубликовано: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
по: William Kelly (15439117)
Опубликовано: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
по: William Kelly (15439117)
Опубликовано: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
по: Zachary Quinn (15052893)
Опубликовано: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
по: Dwight H. Owen (15034782)
Опубликовано: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
по: Dwight H. Owen (15034782)
Опубликовано: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
по: Dwight H. Owen (15034782)
Опубликовано: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
по: Dwight H. Owen (15034782)
Опубликовано: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
по: Dwight H. Owen (15034782)
Опубликовано: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
по: Qingsheng Xu (17078830)
Опубликовано: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
по: Qingsheng Xu (17078830)
Опубликовано: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
по: Evan C. Chen (15054014)
Опубликовано: (2025)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
по: Roberto Carmagnani Pestana (15294422)
Опубликовано: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
по: Ulka N. Vaishampayan (15051039)
Опубликовано: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
по: Ulka N. Vaishampayan (15051039)
Опубликовано: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
по: Ulka N. Vaishampayan (15051039)
Опубликовано: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
по: Ulka N. Vaishampayan (15051039)
Опубликовано: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
по: Srivandana Akshintala (16610490)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nkbkcv1t9ajkqr432ledc8grvm